Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageDebt RatioDebt to EquityEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginGross MarginInterest Coverage RatioInventory AverageInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on SalesTimes Interest Earned

Coherus Oncology (CHRS) Debt to Equity (2016 - 2025)

Historic Debt to Equity for Coherus Oncology (CHRS) over the last 12 years, with Q3 2025 value amounting to $0.42.

  • Coherus Oncology's Debt to Equity rose 18083.98% to $0.42 in Q3 2025 from the same period last year, while for Sep 2025 it was $0.42, marking a year-over-year increase of 18083.98%. This contributed to the annual value of -$0.38 for FY2024, which is 7047.87% up from last year.
  • Latest data reveals that Coherus Oncology reported Debt to Equity of $0.42 as of Q3 2025, which was up 18083.98% from $0.31 recorded in Q2 2025.
  • Over the past 5 years, Coherus Oncology's Debt to Equity peaked at $15.59 during Q1 2022, and registered a low of -$8.66 during Q2 2022.
  • Over the past 5 years, Coherus Oncology's median Debt to Equity value was -$0.52 (recorded in 2024), while the average stood at -$0.14.
  • Data for Coherus Oncology's Debt to Equity shows a peak YoY increase of 256454.41% (in 2022) and a maximum YoY decrease of 190547.44% (in 2022) over the last 5 years.
  • Over the past 5 years, Coherus Oncology's Debt to Equity (Quarter) stood at $0.77 in 2021, then plummeted by 331.19% to -$1.79 in 2022, then grew by 27.71% to -$1.29 in 2023, then surged by 70.48% to -$0.38 in 2024, then soared by 210.45% to $0.42 in 2025.
  • Its last three reported values are $0.42 in Q3 2025, $0.31 for Q2 2025, and -$0.34 during Q1 2025.